Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New hope for hard-to-treat cancers? first human trial begins
Disease control Recruiting nowThis study tests a new experimental drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have spread or cannot be removed. The goal is to find safe doses and see if the drug can shrink tumors. About 450 adults with cer…
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New hope for HER2 cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called VIR-5818, alone or with another drug (pembrolizumab), in people with advanced HER2-positive cancers that have spread. The main goals are to check safety and find the right dose. About 645 adults with various HER2-expressing tumors will take part…
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
New combo therapy aims to silence hepatitis d in patients not helped by current drug
Disease control Recruiting nowThis study tests whether a combination of two experimental drugs (tobevibart and elebsiran) can clear hepatitis D virus from the blood of adults who still have active virus despite taking bulevirtide. About 150 participants aged 18–70 with compensated liver disease will receive t…
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC